BCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioCryst Pharmaceuticals Inc (BCRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term growth potential as indicated by analysts and its recent acquisition of Astria Therapeutics, the current technical indicators, lack of immediate trading signals, and mixed financial performance suggest waiting for a more favorable entry point.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 35.806, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading near its key support level of 9.018. The price trend is weak with a recent -3.84% regular market change.
Analysts have raised price targets and maintained Outperform ratings, citing strong growth potential from the Astria Therapeutics acquisition and peak revenue projections for key products like Orladeyo and navenibart.
The stock has shown weak recent price performance, with a -3.84% regular market change and bearish technical indicators. Additionally, Q4 financials showed a significant drop in net income (-1017.50% YoY) and EPS (-961.54% YoY), despite strong revenue growth.
In Q4 2025, revenue increased significantly by 209.09% YoY to $406.56M, but net income dropped by -1017.50% YoY to $245.85M, and EPS fell by -961.54% YoY to 1.12. Gross margin improved slightly to 97.66%.
Analysts are optimistic about the long-term growth of BioCryst, with price targets raised to $17 and $22 and Outperform ratings maintained. They highlight the company's strategic acquisition of Astria Therapeutics and strong revenue potential from key products.
